Comparison between Maiden Forgings IPO and Sotac Pharmaceuticals IPO.
Maiden Forgings IPO is a SME Bookbuilding IPO proposed to list at BSE SME while Sotac Pharmaceuticals IPO is a SME Bookbuilding proposed to list at NSE SME.
| Maiden Forgings IPO | Sotac Pharmaceuticals IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | BSE SME | NSE SME |
| Lead Managers | Share India Capital Services Pvt.Ltd. | Beeline Capital Advisors Pvt.Ltd. |
| Registrar | Maashitla Securities Pvt.Ltd. | Kfin Technologies Ltd. |
| Market Maker | Share India Securities Ltd. | Sunflower Broking Pvt.Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Maiden Forgings IPO is up to ₹22.64 Cr whereas the issue size of the Sotac Pharmaceuticals IPO is up to ₹31.64 Cr. The final issue price of Maiden Forgings IPO is ₹63.00 per share and of Sotac Pharmaceuticals IPO is ₹111.00 per share.
| Maiden Forgings IPO | Sotac Pharmaceuticals IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹60.00 per share | ₹105.00 per share |
| Issue Price (Upper) | ₹63.00 per share | ₹111.00 per share |
| Issue Price (Final) | ₹63.00 per share | ₹111.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ||
| Market Lot Size | 2000 shares | 1200 shares |
| Fresh Issue Size | 35,94,000 shares | 28,50,000 shares |
| Fresh Issue Size (Amount) | up to ₹22.64 Cr | up to ₹31.64 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 35,94,000 shares | 28,50,000 shares |
| Issue Size Total (Amount) | up to ₹22.64 Cr | up to ₹31.64 Cr |
Maiden Forgings IPO opens on Mar 23, 2023, while Sotac Pharmaceuticals IPO opens on Mar 29, 2023. The closing date of Maiden Forgings IPO and Sotac Pharmaceuticals IPO is Mar 27, 2023, and Apr 03, 2023, respectively.
| Maiden Forgings IPO | Sotac Pharmaceuticals IPO | |
|---|---|---|
| Anchor Bid Date | Mar 28, 2023 | |
| Issue Open | Mar 23, 2023 | Mar 29, 2023 |
| Issue Close | Mar 27, 2023 | Apr 03, 2023 |
| Basis Of Allotment (Tentative) | Mar 31, 2023 | Apr 10, 2023 |
| Initiation of Refunds (Tentative) | Apr 03, 2023 | Apr 11, 2023 |
| Credit of Share (Tentative) | Apr 05, 2023 | Apr 12, 2023 |
| Listing date (Tentative) | Apr 06, 2023 | Apr 13, 2023 |
| Anchor Lockin End date 1 | May 10, 2023 | |
| Anchor Lockin End date 2 | Jul 09, 2023 |
Maiden Forgings IPO P/E ratio is 8.38, as compared to Sotac Pharmaceuticals IPO P/E ratio of 132.14.
| Maiden Forgings IPO | Sotac Pharmaceuticals IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Standalone)
| Company Financials (Restated Consolidated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 100 | 84.63 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 73.37 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 8.38 | 132.14 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹89.54 Cr. | ₹122.66 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 6.87 | 53.1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 16.97 | 68.34 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.66 | 1.12 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹4.10 | ₹3.58 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 6.87 | 43.47 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Maiden Forgings IPO Retail Individual Investors (RII) are offered 22,64,000 shares while in Sotac Pharmaceuticals IPO retail investors are offered 22,64,000 shares. Qualified Institutional Buyers (QIB) are offered 3,60,000 shares in Maiden Forgings IPO and 5,70,000 shares in Sotac Pharmaceuticals IPO.
| Maiden Forgings IPO | Sotac Pharmaceuticals IPO | |
|---|---|---|
| Anchor Investor Reservation | 8,53,200 shares | |
| Market Maker Reservation | 1,90,000 shares | 1,50,000 shares |
| QIB | 3,60,000 shares | 5,70,000 shares |
| NII | 9,70,000 shares | 4,28,400 shares |
| RII | 22,64,000 shares | 9,98,400 shares |
| Employee | ||
| Others | ||
| Total | 35,94,000 shares | 28,50,000 shares |
Maiden Forgings IPO subscribed 1.20x in total, whereas Sotac Pharmaceuticals IPO subscribed 1.60x.
| Maiden Forgings IPO | Sotac Pharmaceuticals IPO | |
|---|---|---|
| QIB (times) | 1.00x | 1.00x |
| NII (times) | 1.42x | 4.04x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 1.12x | 0.91x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 1.20x | 1.60x |
